Background: Citicoline can have beneficial effects both in degenerative and in vascular cognitive decline in a variety of ways (apoptosis inhibition, neuroplasticity potentiation, phospholipid, and acetylcholine (ACh) synthesis). Acetylcholinesterase inhibitors (AChEIs) have been used for treatment of Alzheimer’s disease (AD). When co-administered with cholinergic precursors, they are able to increase the intrasynaptic levels of ACh more than when the single drugs given alone.
Objective: The aim of the present study was to show the effectiveness of oral citicoline plus AChEIs in patients affected with AD.
Methods: This was a retrospective multi-centric case-control study, involving seven Centers for Cognitive Impairment and Dementia in Italy, on 448 consecutive patients aged 65 years old or older affected with AD. 197 patients were treated with an AChEI while 251 were treated with an AchEI + citicoline 1000 mg/day given orally. Cognitive functions were assessed by MMSE, daily life functions by ADL and IADL, behavioral symptoms by NPI, comorbidities by CIRS, and mood by GDS-short form. Tests were administered at baseline (T0), after 3 (T1), and 9 months (T2). The primary outcomes were effects of combined administration versus AChEIs given alone on cognitive functions assessed by MMSE. The secondary outcomes were possible side effects or adverse events of combination therapy versus AChEIs alone.
Results: Patients treated with citicoline plus an AChEI showed a statistically significant increase in MMSE between T0 and T1 (16.88±3.38 versus 17.62±3.64; p = 0.000) and between T1 and T2 (17.62±3.64 versus 17.89±3.54; p = 0.000).
Conclusion: The present study encourages the role of combined administration in disease management by slowing disease progression.
GareriP, PutignanoD, CastagnaA, CotroneoAM, De PaloG, FabboA, ForgioneL, GiacummoA, LacavaR, MarinoS, SimoneM, ZurloA, PutignanoS (2014) Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd patients affected with Alzheimer’s disease: The MEMAGE Study. J Alzheimers Dis41, 633–640.
2.
AmentaF, CarotenutoA, FasanaroAM, ReaR, TrainiE (2012) The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: Interim results. J Neurol Sci15(322), 96–101.
FioravantiM, YanagiM (2005) Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev18(2), CD000269.
5.
HurtadoO, LizasoainI, MoroMÁ (2011) Neuroprotection and recovery: Recent data at the bench on citicoline. Stroke42(Suppl 1), S33–S35.
6.
GriebP (2014) Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs28, 185–193.
7.
GareriP, CastagnaA, CotroneoAM, PutignanoS, De SarroG, BruniAC (2015) The role of citicoline in cognitive impairment: Pharmacological characteristics, possible advantages and doubts for an old drug with new perspectives. Clinical Interv Aging10, 1421–1429.
8.
García-CobosR, Frank-GarcíaA, Gutiérrez-FernándezM, Díez-TejedorE (2010) Citicoline, use in cognitive decline: Vascular and degenerative. J Neurol Sci299, 188–192.
9.
CotroneoAM, CastagnaA, PutignanoS, LacavaR, FantòF, MonteleoneF, RoccaF, MalaraA, GareriP (2013) Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging8, 131–137.
FarlowMR, SallowayS, TariotPN, YardleyJ, MolineML, WangQ, Brand-SchieberE, ZouH, HsuT, SatlinA (2010) Effectiveness and tolerability of high-dose (23mg/d) versus standard-dose 10mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Ther32, 1234–1251.
14.
VincentS, LaneR (2003) PsychogeriatricsRivastigmine in vascular dementia. Int Psychogeriatrics15(Suppl 1), 201–205.
15.
PolinskyRJ (1998) Clinical pharmacology of rivastigmine: A new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther20, 634–647.
16.
GareriP, GallelliL, Ferreri IbbaduG, LacavaR, RussoE, De SarroG. (2005) Melaena following use of the cholinesterase inhibitor rivastigmine. Clin Drug Invest25, 215–217.
17.
MagniE, BinettiG, BianchettiA, RozziniR, TrabucchiM (1996) Mini-Mental State Examination: A normative study in Italian elderly population. Eur J Neurol3, 198–202.
18.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DekoskyST, Barberger-GateauP, DelacourteA, FrisoniG, FoxNC, GalaskoD, GauthierS, HampelH, JichaGA, MeguroK, O’Brien.J, PasquierF, RobertP, RossorM, SallowayS, SarazinM, de SouzaLC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
19.
TayebatiSK, Di TullioMA, TomassoniD, AmentaF (2009) Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. J Neurol Sci283, 187–194.
20.
AmentaF, TayebatiSK, VitaliD, Di TullioMA (2006) Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission. Mech Aging Devel127, 173–179.
DonmezG, OuteiroTF (2013) SIRT1 and SIRT2:Emerging targets in neurodegeneration. EMBO Mol Med5, 344–352.
23.
ZhangF, WangS, GanL, VoslerPS, GaoY, ChenJ (2011) Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol95, 373–395.
24.
MartynovMY, GusevEI (2015) Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. J Exp Pharmacol7, 17–28.
25.
PlatarasC, TsakirisS, AngelogianniP (2000) Effect of CDP-choline on brain acetylcholinesterase and Na(+), K(+)-ATPase in adult rats. Clin Biochem33, 351–357.
KrupinskiJ, FerrerI, BarrachinaM, SecadesJJ, MercadalJ, LozanoR (2002) CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacol42, 846–854.
AgutJ, OrtizJA, WurtmanRJ (2000) Cytidine (5′)diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis. Ann N Y Acad Sci920, 332–335.
31.
GimenezR, RaichJ, AguilarJ (1991) Changes in brain striatum dopamine and acetylcholine receptors induced by chronic CDP-choline treatment of aging mice. Br J Pharmacol104, 575–578.
32.
KakihanaM, FukudaN, SunoM, NagaokaA (1988) Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke19, 217–222.
33.
BiererLM, HaroutunianV, GabrielS, KnottPJ, CarlinLS, PurohitDP, PerlDP, SchmeidlerJ, KanofP, DavisKL (1995) Neurochemical correlates of dementia severity in Alzheimer’s disease: Relative importance of the cholinergic deficits. J Neurochem64, 749–760.
34.
Pardossi-PiquardR, DunysJ, YuG, St George-HyslopP, Alves da CostaC, CheclerF (2006) Neprilysin activity and expression are controlled by nicastrin. J Neurochem97, 1052–1056.
35.
ZhuravinIA, Nalivaeva1NN, KozlovaDI, KochkinaEG, FedorovaYaB, GavrilovaSI (2015) The activity of blood serum cholinesterases and neprilysin as potential biomarkers of mild-cognitive impairment and Alzheimer’s disease. Zh Nevrol Psikhiatr11, 77–85.
AdibhatlaRM, HatcherJF, DempseyRJ (2001) Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke32, 2376–2381.
38.
D’OrlandoKJ, SandageBWJr (1995) Citicoline (CDP-choline): Mechanism of action and effects in ischemic brain injury. Neurol Res17, 281–284.
39.
Scientific Opinion on the safety of “citicoline” as a Novel Food ingredient1 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2013). European Food Safety Authority(EFSA), Parma, Italy; 11, 3421, 22.
40.
PutignanoS, GareriP, CastagnaA, CerquaG, CerveraP, CotroneoAM, FiorilloF, GrellaR, LacavaR, MaddonniA, MarinoS, PluderiA, PutignanoD, RoccaF (2012) Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. Clin Interv Aging7, 113–118.
41.
CastagnaA, CotroneoAM, RuotoloG, GareriP (2016) The CITIRIVAD Study: CITIcoline plus RIVAstigmine in elderly patients affected with Dementia Study. Clin Drug Investig36, 1059–1065.
